• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

New Insights into Gonorrhea Natural History and Protection by 4CMenB, and a Call for More Analyses of Existing Studies and Enhanced Data Collection.

作者信息

White Peter J, Leng Trystan, Nikitin Dariya, Whittles Lilith K

机构信息

MRC Centre for Global Infectious Disease Analysis and NIHR Health Protection Research Unit in Modelling and Health Economics, Imperial College London, London, UK.

Modelling and Economics Unit, UK Health Security Agency, London, UK.

出版信息

Open Forum Infect Dis. 2025 Apr 10;12(5):ofaf214. doi: 10.1093/ofid/ofaf214. eCollection 2025 May.

DOI:10.1093/ofid/ofaf214
PMID:40337724
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12056933/
Abstract
摘要

相似文献

1
New Insights into Gonorrhea Natural History and Protection by 4CMenB, and a Call for More Analyses of Existing Studies and Enhanced Data Collection.对淋病自然史及4CMenB疫苗保护作用的新见解，以及呼吁对现有研究进行更多分析并加强数据收集。
Open Forum Infect Dis. 2025 Apr 10;12(5):ofaf214. doi: 10.1093/ofid/ofaf214. eCollection 2025 May.
2
Prevention of Neisseria gonorrhoeae With Meningococcal B Vaccine: A Matched Cohort Study in Southern California.用脑膜炎球菌 B 疫苗预防淋病奈瑟菌：南加州的一项匹配队列研究。
Clin Infect Dis. 2023 Feb 8;76(3):e1341-e1349. doi: 10.1093/cid/ciac436.
3
4CMenB journey to the 10-year anniversary and beyond.4CMenB 的十年历程及未来展望。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2357924. doi: 10.1080/21645515.2024.2357924. Epub 2024 Jul 8.
4
The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae.基于 B 群脑膜炎奈瑟菌外膜囊泡的疫苗 4CMenB 可诱导针对淋病奈瑟菌的种间保护。
PLoS Pathog. 2020 Dec 8;16(12):e1008602. doi: 10.1371/journal.ppat.1008602. eCollection 2020 Dec.
5
Insight into Prevention of Neisseria Gonorrhoeae: A Short Review.淋病奈瑟菌预防的见解：简短综述
Vaccines (Basel). 2022 Nov 18;10(11):1949. doi: 10.3390/vaccines10111949.
6
Meningococcal vaccine 4CMenB elicits a robust cellular immune response that targets but is not consistently protective against during murine vaginal infection.脑膜炎球菌疫苗4CMenB在小鼠阴道感染期间引发针对[原文此处信息缺失]的强烈细胞免疫反应，但并非始终具有保护作用。
mSphere. 2025 May 27;10(5):e0094024. doi: 10.1128/msphere.00940-24. Epub 2025 Apr 16.
7
Potential public health impacts of gonorrhea vaccination programmes under declining incidences: A modeling study.发病率下降情况下淋病疫苗接种计划对公共卫生的潜在影响：一项建模研究。
PLoS Med. 2025 Feb 7;22(2):e1004521. doi: 10.1371/journal.pmed.1004521. eCollection 2025 Feb.
8
Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK.在英国，高风险淋病人群中使用脑膜炎 B 型疫苗（4CMenB）。
Lancet Infect Dis. 2024 Sep;24(9):e576-e583. doi: 10.1016/S1473-3099(24)00031-8. Epub 2024 Mar 20.
9
Cost-effectiveness of 4CMenB Vaccination Against Gonorrhea: Importance of Dosing Schedule, Vaccine Sentiment, Targeting Strategy, and Duration of Protection.4CMenB疫苗预防淋病的成本效益：给药方案、疫苗认知、靶向策略及保护持续时间的重要性
J Infect Dis. 2025 Feb 4;231(1):71-83. doi: 10.1093/infdis/jiae123.
10
Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol.评价 4CMenB 疫苗在婴幼儿和青少年计划中预防侵袭性脑膜炎球菌病和淋病的效果：方案。
Hum Vaccin Immunother. 2021 May 4;17(5):1450-1454. doi: 10.1080/21645515.2020.1827614. Epub 2021 Jan 11.

本文引用的文献

1
Breakthrough Rectal Infections After Meningococcal B Vaccination: Microbiological and Clinical Features.B 型脑膜炎球菌疫苗接种后突破性直肠感染：微生物学和临床特征
Open Forum Infect Dis. 2024 Nov 4;11(11):ofae562. doi: 10.1093/ofid/ofae562. eCollection 2024 Nov.
2
The potential role of the 4CMenB vaccine in combating gonorrhoea: the need for nuance in interpreting the DOXYVAC trial.4CMenB疫苗在对抗淋病方面的潜在作用：解读DOXYVAC试验时需要注意细微差别。
Lancet Infect Dis. 2024 Sep;24(9):e543. doi: 10.1016/S1473-3099(24)00452-3. Epub 2024 Jul 17.
3
Cost-effectiveness of 4CMenB Vaccination Against Gonorrhea: Importance of Dosing Schedule, Vaccine Sentiment, Targeting Strategy, and Duration of Protection.4CMenB疫苗预防淋病的成本效益：给药方案、疫苗认知、靶向策略及保护持续时间的重要性
J Infect Dis. 2025 Feb 4;231(1):71-83. doi: 10.1093/infdis/jiae123.
4
Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK.在英国，高风险淋病人群中使用脑膜炎 B 型疫苗（4CMenB）。
Lancet Infect Dis. 2024 Sep;24(9):e576-e583. doi: 10.1016/S1473-3099(24)00031-8. Epub 2024 Mar 20.
5
We need estimates of gonorrhoea vaccine protection and symptomaticity by sex and anatomical site.我们需要按性别和解剖部位对淋病疫苗的保护作用及症状发生率进行评估。
Lancet Infect Dis. 2022 Jul;22(7):937. doi: 10.1016/S1473-3099(22)00343-7.
6
Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis.淋病疫苗接种的公共卫生影响和成本效益：综合传播动力学健康经济建模分析。
Lancet Infect Dis. 2022 Jul;22(7):1030-1041. doi: 10.1016/S1473-3099(21)00744-1. Epub 2022 Apr 12.
7
A Gonococcal Vaccine Has the Potential to Rapidly Reduce the Incidence of Neisseria gonorrhoeae Infection Among Urban Men Who Have Sex With Men.淋病球菌疫苗有可能迅速降低城市男男性行为者中淋病奈瑟菌感染的发生率。
J Infect Dis. 2022 Mar 15;225(6):983-993. doi: 10.1093/infdis/jiab581.
8
Assessment of the Potential of Vaccination to Combat Antibiotic Resistance in Gonorrhea: A Modeling Analysis to Determine Preferred Product Characteristics.评估疫苗在防治淋病抗生素耐药性方面的潜力：建模分析以确定首选产品特征。
Clin Infect Dis. 2020 Nov 5;71(8):1912-1919. doi: 10.1093/cid/ciz1241.
9
Improving Control of Antibiotic-Resistant Gonorrhea by Integrating Research Agendas Across Disciplines: Key Questions Arising From Mathematical Modeling.通过整合跨学科研究议程改善对抗生素耐药性淋病的控制：数学建模引发的关键问题
J Infect Dis. 2016 Mar 15;213(6):883-90. doi: 10.1093/infdis/jiv517. Epub 2015 Oct 30.
10
The theoretical impact and cost-effectiveness of vaccines that protect against sexually transmitted infections and disease.预防性传播感染和疾病的疫苗的理论影响和成本效益。
Vaccine. 2014 Mar 20;32(14):1536-42. doi: 10.1016/j.vaccine.2013.11.007.